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Melatonin in children with cancer
Unsupported claims of effectiveness are misleading families
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Recent calls have been made for young cancer patients to be
given melatonin as part of NHS “standard of care” treatment.
The premise is that melatonin “could save lives as well as the
NHS money”—by improving survival and reducing adverse
side effects.1 This has generated understandable media interest.2
Cancer affects one in 500 people under the age of 14 and is a
leading cause of death in childhood. It is highly emotive, with
the potential to have devastating effects on the lives of affected
families who, quite understandably, will go to extremes to
support their children. Reassuringly, five and 10 year survival
rates have doubled since the 1970s,3 with the increases being
attributed to systematic and widespread adoption of collaborative
clinical trials to evaluate new approaches to treatment.4
Although over 80% of young people who have cancer diagnosed
will survive long term, six out of 10 will experience one or more
serious late effects a decade after they completed treatment.5
Consequently, the search for approaches that increase survival
while reducing short and long term morbidity, remains a priority.
Melatonin is an indolamine hormone produced by the pineal
gland.6 7 Its main physiological role seems to be the regulation
of circadian rhythms of sleep, with evidence that is effective in
treating sleep disorders, including prevention and management
of jetlag.8 In association with behavioural modification, it is
used in the management of sleep disorders in children,9 including
those with learning disabilities and those with disrupted sleep
associated with brain tumours.10
Weak evidence
Melatonin’s antioxidant property is the basis for its potential to
inhibit the growth of cancer cells, with studies in vitro and in
animals suggesting antimitotic or immunomodulatory effects.9
Melatonin has been tested as an anti-cancer adjunct in clinical
trials in patients with many different cancers, though only one
trial was in children. The trials have been drawn together in
multiple systematic reviews,10 which have highlighted the need
for stronger evidence of benefit. These reviews often comment
on the moderate to high risk of bias in underlying trials as well
as their heterogeneity. Such weaknesses make pooled estimates
drawn from meta-analysis unreliable and potentially
misleading.11 A clear understanding of the limitations of
systematic reviews is essential when interpreting their findings.
Plain English summaries of findings, including appropriate
caution and signposting to other patient resources, may help to
minimise misinterpretation and any attendant distress.
The only study of melatonin in children with cancer is a
preliminary (phase I) dose finding study, intended primarily to
identify an appropriate dose for further investigation.12 This
study has been presented as a conference abstract but not yet
published in a peer reviewed journal. It showed tolerability, but
side effects included nausea, anorexia, dizziness, fatigue, rashes,
and weight changes. Notably, children being treated with
anthracyclines, a widely used class of anti-cancer drugs in young
people, were excluded because of concerns about the possible
harmful interaction with such chemotherapy.
The media coverage surrounding the use of melatonin has
provoked, in equal measure, interest and concern from families
affected by childhood cancer. Many parents have been left
wondering if they should give melatonin alongside their child’s
treatment and are concerned that information about this
supplement was not available to them earlier. Medical and
nursing professionals in the UK and Ireland believe there is
insufficient evidence to endorse widespread use of melatonin
by children with cancer at this stage13 and that claims of
effectiveness are misleading to families.
Inadequately supported statements from widely trusted sources
may lead families to use melatonin without informing medical
professionals. Such statements may cause additional distress to
families, who are already under immense pressure. As we strive
to offer hope and support to families affected by childhood
cancer, all individuals and organisations should exercise
responsible caution to avoid unintentionally compounding
distress and harm through premature claims of treatment
benefits, particularly improved survival.
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The evidence for melatonin’s use as an anti-cancer agent is
currently weak, and in children effectively non-existent. The
proposal to introduce melatonin as “standard of care” in young
people with cancer is not supportable. Robust evidence from
carefully designed and conducted clinical trials must underpin
all treatments for cancer in young people, and melatonin is no
exception.
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